E-Qure

Company Overview

Snapshot

Founded in January 1988, E-Qure operates with 1–10 employees. The company focuses on developing bioelectrical signal therapy devices. A significant milestone for the company was receiving marketing approval in Israel for its BST Device for chronic wound care in February 2017.

Business overview

E-Qure develops the Bioelectrical Signal Therapy (BST) Device, a technology designed to treat chronic wounds through electrical stimulation. The device functions by mimicking the body's natural electrical currents to stimulate blood flow, oxygen, and local cell regeneration, thereby accelerating wound healing. E-Qure's technology is targeted at severe wounds such as pressure, diabetic, and venous ulcers, serving hospitals, nursing homes, and home-care settings within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In February 2017, E-Qure's BST Device for chronic wound care received marketing approval in Israel. This approval was a critical validation of the company's technology, signaling its readiness for commercial deployment in a regulated market and demonstrating the potential for its bioelectrical signal therapy to address a significant medical need.

Company Intelligence Q&A

What is E-Qure's primary product?

E-Qure's primary product is the Bioelectrical Signal Therapy (BST) Device, which uses electrical stimulation to promote wound healing by inducing local cell regeneration and improving blood flow and oxygenation.

When did E-Qure receive marketing approval for its BST Device in Israel?

In February 2017, E-Qure's BST Device for chronic wound care received marketing approval in Israel.

What types of wounds does the BST Device target?

The BST Device is designed to treat severe chronic wounds, including pressure ulcers, diabetic ulcers, and venous ulcers.

What is the core technology behind E-Qure's device?

E-Qure's technology accelerates wound healing by imitating the natural electrical current in injured skin, using electrodes to emit an electrical field that mimics electrochemical physiology and induces local cell regeneration.

What is the current status of E-Qure?

E-Qure is currently non-active, having ceased operations in May 2023.